Background Adalimumab, a fully human, anti-TNFα monoclonal antibody has been shown to be effective for moderate-to-severe psoriasis in clinical trial setting. However, only a limited number of studies reflect everyday clinical experience with this drug.
Objectives To provide evidence on the efficacy, dose optimization and safety of adalimumab based on everyday clinical experience in a tertiary referral centre for psoriasis, in Greece.
Methods We retrospectively reviewed the records of all patients with moderate-to-severe psoriasis who received adalimumab, in our referral centre, between January 2008 and October 2010.
Results In total, 52 patients were ...
Adalimumab for psoriasis in Greece: clinical experience in a tertiary referral centre is a post from: Skincare
Adalimumab for psoriasis in Greece: clinical experience in a tertiary referral centre via BuzzBlazer.com
No comments:
Post a Comment